Clinical trials: Non-arteritic Ischemic Optic Neuropathy
- Condition Non-arteritic Ischemic Optic Neuropathy
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Non-arteritic Ischemic Optic Neuropathy, Optic Nerve Injuries
Safety and Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION).
The study objectives are to assess any changes in visual acuity and visual field observed following the administration of RPh201 during an overall treatment period of at least 13 consecutive weeks with an option to extended the…
- Trial name
- NCT02045212
- Testing
- RPh201
- Where
- Israel
- Volunteers
- 22 people
- Sponsor
- Regenera Pharma Ltd
Anterior Ischemic Optic Neuropathy, Ischemic Optic Neuropathy
Epidemiology Study of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
The objectives of this study were to: (1) evaluate the natural history of non-arteritic anterior ischemic optic neuropathy (NAION); (2) estimate the population incidence of NAION; and (3) identify potential risk factors for NAION.
- Trial name
- NCT01260324
- Testing
- No intervention given in this observational study
- Volunteers
- 21,283 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Anterior Ischemic Optic Neuropathy
PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
The primary objective of this study is to determine whether the use of PDE5 inhibitors (vardenafil, sildenafil, or tadalafil) increases the risk for the development of NAION.
- Trial name
- NCT00867815
- Testing
- Diagnostic procedures
- Where
- 13 sites in United States, Australia and 1 more
- Volunteers
- 10 people
- Sponsor
- Bayer